andomized Phase 3 Trial (RAMP 301) Will Evaluate the Combination of Avutometinib and Defactinib vs Standard of Care Treatment; Study to Commence in 2H 2023
Recently Published Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination
Company Intends to File for Accelerated FDA Approval for the Combination Based on Mature Data from RAMP 201 and the FRAME Trial
https://finance.yahoo.com/news/verastem-oncology-announces-design-confirmatory-200500596.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.